RxDoctor Payments Data

Leanne Venable, NP

Family · Murfreesboro, TNNPI 1962684878

Payments from drug & device makers

$2,947in general payments, 2019–2025

Across 164 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$484
  • Teva Pharmaceuticals USA, Inc.$316
  • Novo Nordisk$278
  • Otsuka America Pharmaceutical, Inc.$180
  • Lilly USA, LLC$176
  • Biohaven Pharmaceutical Holding Company Ltd.$176
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,947 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$202,062
Medicare patients
296
Services billed
2,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$159,747
NuplazidPimavanserin Tartrate19$93,706
MyrbetriqMirabegron123$47,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$37,136
RytaryCarbidopa/Levodopa24$32,772
FarxigaDapagliflozin Propanediol46$26,024
XareltoRivaroxaban29$21,652
LinzessLinaclotide35$20,555
JardianceEmpagliflozin39$19,372
Breo ElliptaFluticasone/Vilanterol44$19,064
NamzaricMemantine Hcl/Donepezil Hcl32$18,991
JanuviaSitagliptin Phosphate33$18,787
OzempicSemaglutide22$17,850
Memantine Hcl547$17,548
CreonLipase/Protease/Amylase19$17,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$159,747285 claims
AbbVieLinzess, Namzaric, Creon, Vraylar$484$73,300101 claims
GSKTrelegy Ellipta, Breo Ellipta$42$56,20099 claims
AstraZenecaFarxiga$26$26,02446 claims
Boehringer IngelheimJardiance$86$19,37239 claims
MerckJanuvia$50$18,78733 claims
Novo NordiskOzempic$278$17,85022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →